Inventor · disambiguated record
Jeanne Grace Flandez
Also filed as: FLANDEZ JEANNE · FLANDEZ JEANNE GRACE
6 granted patents·6 pending applications·30 citations·filing 2013–2023
80Inventor score
Top patents by PatentIndex Score
12 records- 0196US11859010B2Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2022·Granted Jan 2, 2024·5 cites·13 claims
- 0295US9487590B2Activatable antibodies that bind interleukin-6 receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2013·Granted Nov 8, 2016·15 cites·35 claims
- 0394US12460017B2Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2023·Granted Nov 4, 2025·1 cites·12 claims
- 0492US11472889B2Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2018·Granted Oct 18, 2022·7 cites·18 claims
- 0584US10611845B2Activatable antibodies that bind interleukin-6 receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Apr 7, 2020·2 cites·35 claims
- 0681US2024150478A1Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0781US2024084022A1Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0873US11814410B2Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2018·Granted Nov 14, 2023·0 cites·28 claims
- 0964US2020339694A1Activatable antibodies that bind interleukin-6 receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1061US2015087810A1Matrix Metalloproteinase Substrates And Other Cleavable Moieties And Methods Of Use ThereofCYTOMX THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 1150US2023056336A1Methods and compositions for treating disease using targeted foxp3+cd4+ t cells and cellular suicide agentsKYVERNA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1248US2022110975A1Method for treating disease using foxp3+cd4+ t cellsKYVERNA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →